Thomas Münzel

Showing 1-13 of 13 articles

Effectiveness of additional X-ray protection devices in reducing scattered radiation in radial intervention: the ESPRESSO randomised trial

Anadol R, Brandt M, Merz N, Knorr M, Ahoopai M, Geyer M, Krompiec D, Wenzel P, Münzel T, Gori T

October 23, 2020 | 10.4244/EIJ-D-19-00945

Bioresorbable vascular scaffolds versus everolimus-eluting metallic stents in patients with ST-segment elevation myocardial infarction: 5-year results of the BVS-EXAMINATION study

Brugaletta S, Gori T, Tousek P, Gomez-Lara J, Pinar E, Ortega-Paz L, Schulz E, Kocka V, Münzel T, Cequier A, Buono A, Serruys P, Sabaté M

March 20, 2020 | 10.4244/EIJ-D-19-00773

Interventions for valvular disease

Incidence and in-hospital safety outcomes of patients undergoing percutaneous mitral valve edge-to-edge repair using MitraClip: five-year German national patient sample including 13,575 implants

von Bardeleben R, Hobohm L, Kreidel F, Ostad MA, Schulz E, Konstantinides S, Lankeit M, Feldman T, Münzel T, Keller K

April 16, 2019 | 10.4244/EIJ-D-18-00961

Characteristics and outcome of patients with complex coronary lesions treated with bioresorbable scaffolds: three-year follow-up in a cohort of consecutive patients

Anadol R, Lorenz L, Weissner M, Ullrich H, Polimeni A, Münzel T, Gori T

October 12, 2018 | 10.4244/EIJ-D-17-00410

Everolimus-eluting bioresorbable scaffolds in patients with coronary artery disease: results from the German-Austrian ABSORB RegIstRy (GABI-R)

Nef H, Wiebe J, Kastner J, Mehilli J, Münzel T, Naber C, Neumann T, Richardt G, Schmermund A, Wöhrle J, Zahn R, Riemer T, Achenbach S, Hamm C

December 20, 2017 | 10.4244/EIJ-D-17-00330

Clinical restenosis and its predictors after implantation of everolimus-eluting bioresorbable vascular scaffolds: results from GABI-R

Mehilli J, Achenbach S, Wöhrle J, Baquet M, Riemer T, Münzel T, Nef H, Naber C, Richardt G, Zahn R, Gori T, Neumann T, Kastner J, Schmermund A, Hamm C, Wöhrle J, Richardt G

December 20, 2017 | 10.4244/EIJ-D-17-00291

Twelve-month outcomes after bioresorbable vascular scaffold implantation in patients with acute coronary syndromes. Data from the European Multicenter GHOST-EU Extended Registry

Schnorbus B, Wiebe J, Capodanno D, Brugaletta S, Geraci S, Mehilli J, Latib A, Lesiak M, Jensen C, Mattesini A, Münzel T, Capranzano P, Di Mario C, Naber C, Araszkiewicz A, Colombo A, Caramanno G, Sabaté M, Tamburino C, Nef H, Gori T

October 11, 2017 | 10.4244/EIJ-D-16-00568

Coronary interventions

Predilation, sizing and post-dilation scoring in patients undergoing everolimus-eluting bioresorbable scaffold implantation for prediction of cardiac adverse events: development and internal validation of the PSP score

Ortega-Paz L, Capodanno D, Gori T, Nef H, Latib A, Caramanno G, Di Mario C, Naber C, Lesiak M, Capranzano P, Wiebe J, Mehilli J, Araszkiewicz A, Pyxaras S, Mattesini A, Geraci S, Naganuma T, Colombo A, Münzel T, Sabaté M, Tamburino C, Brugaletta S

April 20, 2017 | 10.4244/EIJ-D-16-00974

Coronary interventions

Early and midterm outcomes of bioresorbable vascular scaffolds for ostial coronary lesions: insights from the GHOST-EU registry

Gori T, Wiebe J, Capodanno D, Latib A, Lesiak M, Pyxaras S, Mehilli J, Caramanno G, Di Mario C, Brugaletta S, Weber J, Capranzano P, Sabaté M, Mattesini A, Geraci S, Naber C, Araszkiewicz A, Colombo A, Tamburino C, Nef H, Münzel T

August 5, 2016 | 10.4244/EIJY15M09_10

Percutaneous coronary intervention with everolimus-eluting bioresorbable vascular scaffolds in routine clinical practice: early and midterm outcomes from the European multicentre GHOST-EU registry

Capodanno D, Gori T, Nef H, Latib A, Mehilli J, Lesiak M, Caramanno G, Naber C, Di Mario C, Colombo A, Capranzano P, Wiebe J, Araszkiewicz A, Geraci S, Pyxaras S, Mattesini A, Naganuma T, Münzel T, Tamburino C

February 20, 2015 | 10.4244/EIJY14M07_11

Early outcome after implantation of Absorb bioresorbable drug-eluting scaffolds in patients with acute coronary syndromes

Gori T, Schulz E, Hink U, Wenzel P, Post F, Jabs A, Münzel T

January 20, 2014 | 10.4244/EIJV9I9A176

The impact of gender on fractional flow reserve measurements

Fineschi M, Guerrieri G, Orphal D, Palmerini E, Münzel T, Warnholtz A, Pierli C, Gori T

July 26, 2013 | 10.4244/EIJV9I3A58

How should I treat a patient with typical angina, typical angiography, negative FFR?

Jabs A, Hink U, Fineschi M, Münzel T, Gori T

May 21, 2013 | 10.4244/EIJV9I1A22

Latest news

NEW ISSUE

Robotics, AI and Imaging State of The Art; Bleeding Risk and Mortality in CAD; Treating Refractory Angina by Coronary Sinus Narrowing; and more

September 20, 2021

STATE OF THE ART

Robotics, imaging, and artificial intelligence in the catheterisation laboratory

Rafael Beyar et al.

September 20, 2021

AHEAD OF PRINT

ViV TAVI vs repeat SAVR

Monil Majmundar et al.

September 15, 2021

AHEAD OF PRINT

Thrombectomy for ischaemic stroke

Christopher A. Rajkumar et al.

September 10, 2021

EDITORIAL

Walking the tightrope between ischaemia and bleeding

Michelle L. O’Donoghue et al.

September 20, 2021

EDITORIAL

Microvascular dysfunction endotypes and outcomes

Christos V. Bourantas et al.

September 20, 2021

EDITORIAL

Coronary sinus reducer therapy for refractory angina: is it ready for prime time?